Avalo Therapeutics AVTX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $14.05M+5.9% | $13.27M-2.6% | $13.62M-3.2% | $14.07M+54.3% | $9.12M+11.5% | ||
| $6.85M+4.9% | $6.53M+17.2% | $5.58M+6.4% | $5.24M-5.5% | $5.55M+6.0% | ||
| $17K+6.3% | $16K-72.9% | $59K-56.0% | $134K-0.7% | $135K+98.5% | ||
| $20.9M+5.6% | $19.8M+3.1% | $19.2M-0.6% | $19.32M+31.7% | $14.67M+8.6% | ||
| -$20.9M-5.9% | -$19.74M-2.8% | -$19.2M+0.6% | -$19.32M-31.7% | -$14.67M-10.2% | ||
| $803K-18.4% | $984K-11.9% | $1.12M+1.4% | $1.1M-4.0% | $1.15M-5.2% | ||
| $1.28M— | —— | -$11.42M-697% | -$1.43M-194% | $1.53M— | ||
| -$19.62M-44.4% | -$13.59M+55.6% | -$30.61M-47.5% | -$20.75M-57.9% | -$13.14M+62.7% | ||
| $12K-90.8% | $130K+1,082% | $11K-31.3% | $16K+100% | $8K-93.0% | ||
| -$19.63M-43.1% | -$13.72M+55.2% | -$30.63M-47.5% | -$20.77M-57.9% | -$13.15M+62.8% | ||
| -$0.98-165% | -$0.37+83.1% | -$2.19-14.1% | -$1.92-53.6% | -$1.25— | ||
| -$0.98-165% | -$0.37+83.1% | -$2.19-14.1% | -$1.92-53.6% | -$1.25+84.3% | ||
| 20.1M+50.0% | 13.4M-4.3% | 14M+29.3% | 10.8M+3.0% | 10.5M+40.3% | ||
| 20.1M+50.0% | 13.4M-4.3% | 14M+29.3% | 10.8M+3.0% | 10.5M+138% | ||
| $480K+102% | -$24.2M-293% | $12.53M+395% | $2.53M+566% | $380K+104% | ||
| $803K-18.4% | $984K-11.9% | $1.12M+1.4% | $1.1M-4.0% | $1.15M-5.2% | ||
| -$19.7M-43.9% | -$13.69M+55.2% | -$30.55M-46.9% | -$20.8M-58.2% | -$13.15M+62.8% | ||
| -$74K-374% | $27K-64.0% | $75K+321% | -$34K— | $0— | ||
| $14.05M+5.9% | $13.27M-2.6% | $13.62M-3.2% | $14.07M+54.3% | $9.12M+11.5% | ||
| -$20.9M-5.9% | -$19.74M-2.8% | -$19.2M+0.6% | -$19.32M-31.7% | -$14.67M-10.2% | ||
| -$20.88M-5.9% | -$19.73M-3.1% | -$19.14M+0.2% | -$19.18M-32.0% | -$14.53M-9.7% | ||
| -$20.88M-5.9% | -$19.73M-3.1% | -$19.14M+0.2% | -$19.18M-32.0% | -$14.53M-9.7% | ||
| -$20.9M-5.9% | -$19.74M-2.8% | -$19.2M+0.6% | -$19.32M-31.7% | -$14.67M-10.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Avalo Therapeutics's revenue?
- Avalo Therapeutics (AVTX) generated $500.0K in revenue over the trailing twelve months, down 38.0% year over year.
- Is Avalo Therapeutics profitable?
- Avalo Therapeutics is not currently profitable: it reported a net loss of $84.7M over the trailing twelve months, a -7965.8% net margin.
- What are Avalo Therapeutics's profit margins?
- Gross margin is 182.0% and operating margin is -15536.1%, with a -7965.8% net margin.
- What is Avalo Therapeutics's earnings per share?
- Avalo Therapeutics's diluted EPS over the trailing twelve months is $-5.46.
- Where does Avalo Therapeutics's income statement data come from?
- Every line is extracted from Avalo Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
